Data shows statistically significant improvement after 3 months of treatment in both objective and subjective measures
HOD HASHARON, Israel, Jan. 10, 2019 /PRNewswire/ — Wize Pharma, Inc. (“Wize Pharma” or the “Company”) (OTCQB: WIZP), a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced publication of data, generated in an investigator initiated study conducted in Hungary during 2016, entitled “Treatment of Moderately Severe Sjögren’s Syndrome-Related Dry Eye without Immunomodulation: A Self-Controlled, Unmasked Study,” in the peer-reviewed journal ECronicon. The publication, authored by Huba J. Kiss, et al, describes outcomes from an open label study of 21 patients and evaluated improvement of objective and subjective measures associated with severe Sjögren’s syndrome-related dry eye.
The single arm study recruited subjects from the Corneal and Eye surface disease outpatient unit of the Department of Ophthalmology at the Semmelweis University in Budapest, Hungary, and included 18 women and 3 men with a mean age of 60.4 years. Each patient self-administered LO2A 4 times a day to each eye for 3 months. The majority of patients had tried at least one other artificial eye product for the treatment of dry eye without marked relief of symptoms. The data showed improvements in lissamine green staining, OSDI and LIPCOF score, but did not show any improvement in basal tear secretion. Please see: https://www.ecronicon.com/ecop/pdf/ECOP-10-00394.pdf
“We are excited about the publication of this data using LO2A in the treatment of severe Sjögren’s Syndrome-Related Dry Eye as it demonstrates the potential of our product in this very large and diverse market. Patients with this condition regularly experience quality of life issues and there are currently limited options available for treatment of their symptoms,” said Wize Pharma’s chairman, Noam Danenberg. He continued, “The Company continues to advance its strategic goals, focused on the clinical development program pursuing US approval and strategic alliances.”
About Wize Pharma, Inc.
Wize Pharma, Inc. is a clinical-stage biopharmaceutical company currently focused on the treatment of ophthalmic disorders, including dry eye syndrome (“DES”). Wize Pharma has in-licensed certain rights to purchase, market, sell and distribute a formula known as LO2A, a drug developed for the treatment of DES, and other ophthalmological illnesses, including conjunctivochalasis (“CCH”) and Sjögren’s Syndrome. Wize Pharma is currently conducting a Phase II trial of LO2A for patients with CCH and a Phase IV study for LO2A for DES in patients with Sjögren’s. LO2A is currently registered and marketed by its inventor in Germany and Switzerland for the treatment of DES, in Hungary for the treatment of DES and CCH and in the Netherlands for the treatment of DES and Sjögren’s. Wize Pharma’s strategy involves engaging local or multinational distributors to handle the distribution of LO2A.
Forward Looking Statements
Wize Pharma cautions you that statements in this press release that are not a description of historical fact are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words referencing future events or circumstances such as “expect,” “intend,” “plan,” “anticipate,” “believe,” and “will,” among others. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon Wize Pharma’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks related to the substantial debt that we have incurred; our needs for additional financing; our dependence on a single compound, LO2A and on the continuation of our license to commercialize LO2A; our inability to expand our rights under our license of LO2A; the initiation, timing, progress and results of our trials and product candidate development efforts; our ability to advance LO2A into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for LO2A, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of LO2A; our ability to establish and maintain corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering LO2A and our ability to operate our business without infringing the intellectual property rights of others; estimates of our expenses, future revenues, and capital requirements; competitive companies, technologies and our industry; and statements as to the impact of the political and security situation in Israel on our business. More detailed information about the risks and uncertainties affecting Wize Pharma is contained under the heading “Risk Factors” included in Wize Pharma’s Annual Report on Form 10-K filed with the SEC on March 29, 2018, and in other filings that Wize Pharma has made and may make with the SEC in the future. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Wize Pharma does not undertake any obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made whether as a result of new information, future events or otherwise, except as may be required by law.